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A b s t r a c t
Introduction: The aim of the study was to assess the arterial stiffness and 
serum levels of selected metalloproteinases (MMPs) in hypertensive pa-
tients and their changes following antihypertensive therapy. 
Material and methods: The study group consisted of 95 patients with es-
sential arterial hypertension (HT) stage 1 or 2 (mean age: 53.1 ±13.0 years). 
The control group consisted of 31 normotensives of the same age range. 
Hypertension patients were randomized to one of the following monother-
apies for 6 months: quinapril, losartan, amlodipine, hydrochlorothiazide or 
bisoprolol. Carotid-femoral pulse wave velocity (PWV) was measured using 
a  Complior device. Serum concentrations of MMPs (proMMP-1, MMP-2, 
MMP-3, MMP-9) and plasma concentration of tissue inhibitor of MMPs 
(TIMP-1) were measured using ELISA.
Results: Pulse wave velocity and serum concentrations of MMP-2 and MMP-9 
were higher in HT patients than in the control group. In HT patients PWV 
was significantly associated (R2 = 0.41) with age (B = 0.408, p = 0.00027), 
systolic blood pressure (SBP) (B = 0.441, p = 0.0011), and MMP-3 (B = 0.204, 
p = 0.0459). After 6 months of treatment, regardless of the agent used, we ob-
served a significant decrease of PWV, SBP, MMP-2 and MMP-3 and an increase 
of TIMP-1 plasma concentration. The decrease of PWV was significantly asso-
ciated with a decrease of SBP (R2 = 0.07, B = 0.260, p = 0.015) only. 
Conclusions: In patients with arterial hypertension, beside age and systolic 
blood pressure, the determinants of arterial stiffness include serum MMP-3 
concentration. For drugs compared in the study with the same hypotensive 
effect obtained, the arterial stiffness reduction effect is not dependent on 
the drug used. Systolic blood pressure is one of the independent factors 
responsible for the reduction of arterial stiffness in the course of antihyper-
tensive treatment.
Key words: arterial hypertension, antihypertensive treatment, matrix 
metalloproteinases, arterial stiffness.
Introduction
Stiffness of the large arteries is an important factor in the pathogen-
esis of arterial hypertension and its complications. The most commonly 
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used method in the assessment of arterial stiff-
ness, carotid-femoral (aortic) pulse wave velocity 
(PWV), is a strong predictor of survival for the gen-
eral population, and is not limited to patients with 
hypertension only [1, 2]. The 2013 guidelines of 
the European Society of Hypertension (ESH) and 
the European Society of Cardiology (ESC) not only 
recommend the measurement of carotid-femoral 
PWV in cardiovascular risk stratification in hyper-
tensive patients (class IIa recommendation, level 
of evidence B) but also emphasize that it is pos-
sible to achieve at least partial reversibility of this 
asymptomatic organ damage following antihyper-
tensive treatment [3]. The reduction of aortic PWV 
during antihypertensive therapy in patients with 
end stage renal disease (ESRD) has been associat-
ed with an improved survival prognosis [4]. A PWV 
lowering effect has been previously described for 
many antihypertensive drugs, primarily for angio-
tensin-converting enzyme inhibitors and angio-
tensin receptor blockers [5–9]. According to some 
authors, the effect of reducing arterial stiffness, 
which has been described for selected antihyper-
tensive agents, is independent of the lowering of 
blood pressure by these agents [10, 11]. Thus, it 
should be concluded that the effect of reducing 
arterial stiffness depends on other (non-antihy-
pertensive) properties of certain drugs or classes 
of drugs.
The development of arterial stiffness is associ-
ated with changes in the composition, proportion 
and physical properties of the structural proteins 
of the vascular wall, especially collagen and elas-
tin [12, 13]. The relationship between the plasma 
concentration of collagen type I and type III me-
tabolites and the stiffness of large arteries under 
antihypertensive medication with quinapril has 
been described previously [14, 15]. Also, a reduc-
tion in the plasma concentration of carboxy-termi-
nal collagen type I propeptide (PICP) was observed 
with use of this drug [8]. Connective tissue matrix 
metalloproteinases (MMPs) and their tissue inhib-
itors play a key role in the metabolism of the struc-
tural proteins of the vascular wall.
The importance of MMPs in vascular wall re-
modeling is not limited to their direct effect as 
proteolytic enzymes in the metabolism of struc-
tural proteins. They are also involved in numerous 
processes such as inflammation, fibrosis, angio-
genesis and cell apoptosis [13, 16–18]. Therefore 
in many diseases with the contribution of a vas-
cular pathology component, e.g. atherosclerosis, 
plaque complications, various types of vasculitis, 
diabetes, and chronic kidney disease, the complex 
role of MMPs is often the subject of research [19–
24]. In the literature, there are reports on the rela-
tionship between the activity of MMPs and their 
tissue inhibitors and arterial stiffness parameters. 
McNulty et al. described a  strong positive cor-
relation between plasma levels of MMP-1 (colla-
genase, mainly responsible for the degradation 
of type I collagen) and carotid-femoral PWV, and 
a weak negative correlation between the TIMP-1/
MMP-1 ratio and PWV [14]. For MMP-2 and MMP-9 
gelatinases, the effect on vascular remodeling 
[25], the destruction of elastin laminae and their 
role in the formation of an aortic aneurysm are 
described [26]. Also, a relationship between their 
elevated plasma levels and arterial stiffness [27] 
was observed.
MMP-3 (stromelysin-1), a  metalloproteinase 
with a  very broad spectrum of activities, includ-
ing the activation of other metalloproteinases 
such as MMP-1 and MMP-9 (degrading fibrillar 
collagen and gelatin, respectively), may play an 
initiating role in the remodeling and stiffening of 
the walls of large arteries [28]. Overexpression 
of the MMP-3 gene observed in homozygotes 5A 
of the promoter gene polymorphism (5A/6A) was 
associated with a higher MMP-3 protein level in 
the aorta and higher aortic characteristic imped-
ance – an important parameter of aortic stiffness 
[29]. It may be hypothesized that the effect of an-
tihypertensive drugs on arterial stiffness depends 
on their impact on MMP activity. Subsequently, 
a variety of effects on arterial stiffness originate 
from various effects on metalloproteinases.
There are only a few reports which link a reduc-
tion in arterial stiffness during antihypertensive 
treatment with changes in the activity of metal-
loproteinases and their inhibitors, and they are 
mostly based on small groups of patients [30].
Moreover, the available literature data on plas-
ma concentrations of metalloproteinases and 
their inhibitors in patients with arterial hyperten-
sion, as well as data on changes in these param-
eters after antihypertensive therapy, are often in-
consistent and sometimes contradictory [31, 32].
The objective of the study was to assess arteri-
al stiffness and serum levels of selected metallo-
proteinases in patients with arterial hypertension 
and changes in the analyzed parameters following 
treatment with different antihypertensive drugs.
Material and methods
The study was a scheduled as prospective trial. 
The study group comprised patients from an out-
patient hypertension clinic. Patients with essential 
arterial hypertension stage 1 and 2 according to 
the 2013 ESH/ESC Guidelines were enrolled, i.e. ar-
terial blood pressure (BP) values ≥ 140/90 mm Hg 
and < 180/110 mm Hg [3], aged 30–75 years, both 
women and men. 
The diagnosis of hypertension, which allowed 
inclusion in the study, was established based on 
blood pressure measurements performed twice, 
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1 week apart, with BP values as above. The mea-
surements were performed in standard condi-
tions, after 5 min rest, in a sitting position on the 
non-dominant arm (the mean of the two mea-
surements taken at an interval of 1 min).
In patients with previously diagnosed and 
treated hypertension, these measurements were 
made after a minimum two-week drug withdrawal 
period. Enrollment in the study group was com-
pleted after reaching the sample size estimated in 
Power Sample Size analysis considered sufficient 
to demonstrate a  significant difference between 
the compared treatment groups in: blood pressure 
parameters, carotid-femoral PWV and plasma lev-
els of MMP-3. Finally, the study group included 
95 patients with hypertension (51 men and 44 
women). Exclusion criteria for the study were: pre-
vious history of coronary artery disease, i.e. myo-
cardial infarction, angina pectoris, a history of cor-
onary revascularization, as well as cardiac valvular 
disease, atrial fibrillation, prior stroke or transient 
ischemic attack, antiplatelet, anticoagulant or 
lipid-lowering therapy, acute or chronic inflam-
mation, cancer, kidney or liver failure. Diabetic 
patients treated with insulin were also excluded.
A  control group of 31 people without hyper-
tension (established by interview and at least 
two years of medical records of blood pressure 
measurements with no values ≥ 140/90 mm Hg) 
in the same age range as the study group, with 
the same proportion of women and men and the 
same incidence of smoking, was selected on the 
basis of the same exclusion criteria from patients 
reporting to periodic preventive checkups at the 
outpatient clinic.
Diabetes was diagnosed based on the WHO 
criteria [33]. Obesity was diagnosed based on the 
value of the body mass index (BMI) ≥ 30 kg/m2. Pa-
tients smoking one or more cigarettes a day for the 
past 6 months were considered active smokers.
In the group of hypertensive patients, 57 (60%) 
were antihypertensive therapy naïve, while 38 pa-
tients (40%) had been previously treated with one 
or a  combination of two antihypertensive drugs 
at low doses. 
In this group 7 patients received previously 
slow release indapamide 1.5 mg as a monother-
apy during the last 1–4 months, 6 patients were 
treated with lisinopril 5 to 10 mg twice daily as 
monotherapy for a  period of 2–3 months, 6 pa-
tients with perindopril 5 mg once daily for a peri-
od of 1–3 months, 4 patients with valsartan 80 mg 
once daily for a period of 1–3 months, 4 patients 
were treated with verapamil 120 mg/day for 1–3 
months, 3 patients with carvedilol 6.125 mg to 
12.5 mg twice daily for a period of 1–4 months, 
2 patients with metoprolol succinate 50 mg/day, 
one for a period of 2 months and the second for 
3 months, 6 patients were treated with combina-
tion therapy indapamide 0.625 mg plus perindo-
pril 2.5 mg once daily for 2–3 months. 
In the diabetic subgroup (6 patients), 3 were 
treated with metformin 500–850 mg/d before and 
then during the study period. Other medications 
during the study (including statins) were prohib-
ited. A low salt and low cholesterol diet was rec-
ommended for all participants. In some cases for 
a short time (no longer than 1 week) nonsteroid 
anti-infammatory drug (NSAIDs) were used.
Previously administered antihypertensive treat- 
ment was discontinued at least 2 weeks before 
the inclusion of patients in the study. Using a com-
puter-generated randomization list, patients with 
primary hypertension were allocated to five equal 
(n = 19) groups receiving monotherapy with one 
of the following five drugs for 6 months: quinapril, 
amlodipine, hydrochlorothiazide, losartan or bi-
soprolol. The initial dosage of drugs from the 
randomization visit were given once a  day and 
were as follows: quinapril 20 mg, amlodipine 
5 mg, hydrochlorothiazide 25 mg, losartan 50 mg 
or bisoprolol 5 mg. If the blood pressure goal of less 
than 140/90 mm Hg was not achieved at the visit 
after a month of treatment, the dose was doubled. 
Thus, for five months in the group treated with 
quinapril, 18 (95%) patients received a  dose of 
40 mg once a day, in the group treated with am-
lodipine, 12 (63%) patients received one dose of 
10 mg a day, in the group of hydrochlorothiazide 
12 (63%) patients treated  received a  dose of 
50 mg once a day, 16 (84%) patients in the group 
treated with losartan received a  dose of 50 mg 
twice a day and 12 (63%) patients in the group 
treated with bisoprolol received a dose of 10 mg 
once a day. Further control visits were carried out 
after three and 6 months of treatment. The pro-
portion of patients who achieved a blood pressure 
reading of < 140/90 mm Hg at visits after 3 and 
6 months did not differ significantly in all thera-
peutic subgroups, and ranged from 74 to 77%.
Study procedures
Before any study procedure all subjects signed 
an informed consent form. The Jagiellonian Uni-
versity Ethics Committee approved the protocol of 
the study (decision number: KBET/7/B/2007).
During each visit, blood pressure measure-
ments were performed under standard condi-
tions, twice at an interval of one minute on the 
non-dominant arm, after five minutes rest in the 
sitting position, in accordance with the recom-
mendations of the European Society of Hyper-
tension [34], using the Omron M5-I oscillometric 
device (Omron Healthcare Co., Japan) [35]. The av-
erage of the obtained values was used for further 
analyses. Carotid-femoral PWV was measured at 
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each visit with a  Complior device (Colson, Garg-
es les Genosse, France; software version 2.1) [36]. 
The PWV measurements were made in accor-
dance with the standards recommended by the 
“Expert consensus document on arterial stiffness: 
methodological issues and clinical applications” 
published in 2006 [1], as well as the “Expert con-
sensus document on the measurement of aortic 
stiffness in daily practice using carotid-femo-
ral pulse wave velocity” published in 2012 [37]. 
However, for a more effective comparison of our 
results with those previously published, the dis-
tance measured on the body surface between the 
carotid and femoral arteries was not multiplied 
by 0.8 as recommended by the latter document 
[37]. After overnight fasting, blood was collected 
from the antecubital vein. Measurements of se-
rum concentrations of glucose, creatinine, total 
cholesterol, high-density lipoprotein (HDL)-cho-
lesterol, low-density lipoprotein (LDL)-cholesterol 
and triglycerides were performed. Blood samples 
for the measurement of serum concentrations of 
metalloproteinases (proMMP-1, MMP-2, MMP-3 
and MMP-9) and TIMP-1 were centrifuged at 3000 g, 
then the plasma was separated and samples 
stored at –75°C until analysis. Serum concentra-
tions of metalloproteinases (proMMP-1, MMP-2, 
MMP-3, MMP-9) and the plasma concentration of 
TIMP-1 were measured at the initial visit and after 
6 months of treatment in all groups. TIMP-1 plas-
ma concentrations were measured using an ELISA 
kit (Human TIMP-1 Immunoassay, Quantikine, 
R&D Systems Europe, Ltd. Abingdon, UK) with an 
inter-assay variation below 4.9% and intra-assay 
variation below 5.0%. The concentration of serum 
metalloproteinases was measured using kits from 
R&D Systems Europe Ltd, Abingdon, UK. Human 
pro-MMP-1 (inter-assay/intra-assay variation be- 
low 5.%/6.7%), Human MMP-2 (inter-assay/in-
tra-assay variation below 7.4%/5.3%), Human 
MMP-3 (inter-assay/intra-assay variation below 
7.9%/5. 7%) and Human MMP-9 with inter-assay/
intra-assay variation below 6.9%/2.9% were used.
Statistical analysis
Database management and statistical analysis 
were performed with SAS software (SAS Institute, 
Cary, NC), version 9.1. The SAS Power and Sample 
Size application (PSS) was used to estimate suf-
ficient sample sizes to achieve adequate power. 
Variables were analyzed for normal distribution by 
the Shapiro-Wilk statistic. The means and propor-
tions were compared using the t-test and the χ2 
test, respectively. The repeated measures analysis 
of variance, followed by Tukey’s post-hoc tests, 
was implemented for the comparison of contin-
uous parameters of interest in the study groups. 
Possible covariates of the changes in PWV during 
follow-up were investigated using multiple regres-
sions, with the F-value for independent variables 
to enter and stay in the model set at 0.10. 
P-values < 0.05 were considered statistically 
significant.
Results
Comparison of clinical characteristics of the 
study and control groups before treatment and at 
the visit after 6 months is shown in Table I.
Comparison of treatment groups at the first 
visit (randomization) before treatment and after 
6 months of treatment in the study group is 
shown in Table II.
During the initial visit, the treated and control 
groups did not differ significantly with respect to 
age, gender, number of patients with diabetes or 
smoking before treatment.
Mean systolic and diastolic blood pressure 
and carotid-femoral PWV were significantly high-
er in the study group. Plasma concentrations of 
total cholesterol and LDL-cholesterol and serum 
concentrations of MMP-2 (231.8 (33.1) vs. 214.2 
(42.7), p = 0.022) and MMP-9 (358.1 (165.4) vs. 
290.6 (157.7), p = 0.047) were also higher in the 
study group than in the control group. At the 
start of the study, the treated and control groups 
did not differ in other studied concentrations of 
metalloproteinases and TIMP-1.
In the control group, there were no significant 
differences in blood pressure, carotid-femoral 
PWV, plasma concentrations of metalloproteinas-
es or TIMP-1, nor in total cholesterol, LDL or other 
biochemical parameters between the initial visit 
and the final visit (after 6 months) (Table I).
There were no significant differences in age, 
gender, body weight, concentrations of plasma 
lipids, glucose, or creatinine (Table II), calculated 
BMI or the incidence of diabetes or smoking (data 
not included in Table II) between the five random-
ly selected therapeutic subgroups at the initial 
visit. Subgroups randomly assigned to treatment 
with quinapril, amlodipine, hydrochlorothiazide, 
losartan and bisoprolol did not differ before treat-
ment with respect to blood pressure, carotid-fem-
oral PWV values, concentrations of metallopro-
teinases or TIMP-1 (Table II). During the 6-month 
observation period, patients were not taking any 
other medications besides the ones being stud-
ied. At the final visit, there was no significant dif-
ference in BMI, plasma lipids, or glucose and cre-
atinine levels between the therapeutic subgroups. 
The heart rate was significantly lower only in the 
group treated with bisoprolol. Before treatment, in 
the study group, multiple regression analysis for 
the independent variable carotid-femoral PWV 
was performed. Blood pressure, age, gender, body 
mass index plasma concentrations of investigated 
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metalloproteinases as well as total cholesterol and 
LDL values were included in the regression model. 
Significant associations (R2 = 0.41, p = 0.000003) 
of PWV with age (B = 0.408, p = 0.00027), SBP 
(B = 0.441, p = 0.0011) and serum concentrations 
of MMP-3 (B = 0.204, p = 0.0459) were found. In 
a  regression analysis in the control group, based 
on the same model, PWV was related only to age 
(R2 = 0.22, B = 0.471; p = 0.011).
Effect of antihypertensive therapy
The analysis of variance (ANOVA) showed that, 
in the course of treatment in all therapeutic sub-
groups there was a significant reduction of systol-
ic and diastolic blood pressure and carotid-femo-
ral PWV. There were no significant differences in 
the magnitude of these effects between the sub-
groups (Table III).
The analysis of covariance (ANCOVA) adjusted 
for age, gender, the extent of the reduction of sys-
tolic blood pressure (ΔSBP) and the initial value 
of PWV did not show a  significant difference in 
the magnitude of the decrease in PWV (ΔPWV) 
between the compared therapeutic subgroups 
(Figure 1).
After 6 months of treatment, regardless of the 
drug used, there was a  significant decrease in 
plasma concentrations of MMP-2 (p = 0.039) and 
MMP-3 (p = 0.0001) and an increase in plasma 
concentration of TIMP-1 (p = 0.0001) (Table IV). 
There were no significant changes in the con-
centrations of other metalloproteinases in all 
subgroups of the study group between the initial 
and final visit. To analyze the factors affecting the 
observed decrease in PWV (ΔPWV), multiple re-
gression analysis was performed which included 
the following variables in the regression model: 
age, sex, body mass index, total cholesterol level, 
initial PWV, a reduction of the systolic blood pres-
sure (ΔSBP), a decrease in MMP-3 concentration 
(ΔMMP-3), a  decrease in MMP-2 concentration 
(ΔMMP-2), and an increase in TIMP-1 (ΔTIMP-1) 
and type of medication. The reduction of PWV 
was significantly associated with a  decrease in 
SBP (B = 0.02, p = 0.01), BMI (B = 0.06, p = 0.028) 
and PWV value at the initial visit (B = –0.37, 
p < 0.001).
Table I. Comparison between study and control group
Variable Baseline After 6-month follow-up
Study group
(N = 95)
Control group
(N = 31)
P-value Study group
(N = 95)
Control group
(N = 31)
Age [years] 53.1 (13.0) 53.0 (13.2)  0.97 53.1 (13.0) 53.0 (13.2)
Male gender (%) 51 (53.6) 16 (51.6) 0.94 51 (53.6) 16 (51.6)
Body weight [kg] 80.3 (14.8) 71.5 (10.9) 0.003 79.7 (14.2) 71.5 (10.9)
Height [cm] 169.7 (8.4) 169.9 (8.8) 0.90
Obese patients, n (%) 12 (12.6) 2 (6.4) 0.006 12 (12.6) 2 (6.4)
Patients with diabetes type 2,  
n (%)
6 (6.3) 2 (6.4) 0.87 6 (6.3) 2 (6.4)
Smokers, n (%) 12 (12.6) 4 (12.9) 0.56 12 (12.6) 4 (12.9)
HR [bpm] 73.1 (10.8) 72.1 (7.4) 0.62 69.6 (12.3) 70.2 (7.7)
SBP [mm Hg] 153.5 (19.4)  131.1 (14.2) < 0.0001 136.9 (15.4) 129.4 (11.0)
DBP [mm Hg] 94.2 (10.3)   82.5 (8.0) < 0.0001 85.1 (9.3) 80.8 (8.5)
PWV [m/s] 10.6 (1.6) 9.8 (1.2) 0.011 10.0 (1.7) 9.7 (1.4)
Creatinine [µmol/l]  67.6 (13.0) 65.4 (11.6) 0.38 65.8 (16.1) 67.8 (11.5)
Glucose [mmol/l] 5.1 (0.9) 4.9 (0.9) 0.65 5.0 (0.7) 5.0 (0.9)
Total cholesterol [mmol/l] 5.4 (0.9) 4.7 (0.9) 0.001 5.12 (0.6) 4.7 (0.8)
Triglycerides [mmol/l] 1.5 (0.7) 1.3 (0.7) 0.18 1.66 (0.7) 1.46 (0.6)
HDL [mmol/l] 1.4 (0.4) 1.5 (0.5) 0.21 1.41 (0.4) 1.58 (0.4)
LDL [mmol/l] 3.3 (0.8) 2.6 (0.9) 0.001 2.97 (0.6) 2.59 (0.7)
Data are given as mean (SD) or number (n) (percentage %); HR – heart rate, SBP – office systolic blood pressure, DBP – office diastolic 
blood pressure, PWV – carotid-femoral pulse wave velocity, HDL – high-density lipoprotein, LDL – low-density lipoprotein. P-value for the 
comparison between study and control group at the baseline. The differences (p-values) between study and control group after a 6-month 
period did not differ from baseline p-values. 
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Discussion
The most important variable analyzed in our 
study, i.e. carotid-femoral PWV, was significantly 
higher in hypertensive patients than in the con-
trol group. In addition, the average value of PWV 
(10.6 m/s) in the analyzed group of patients with 
hypertension significantly exceeded the average 
reference PWV value for the European population of 
healthy people aged 50–59 years, which is 8.3 m/s 
[38]. The majority of patients in our study group 
were within this age range. 
Similarly to other studies, the PWV value in our 
hypertensive patients in the multiple regression 
analysis was significantly related to its typical de-
terminants, i.e. age and systolic blood pressure [1, 
12, 13, 38].
Therefore, this study-obtained association be-
tween PWV and the plasma concentration of MMP-3 
(stromelysin-1) is the study novelty and has impor-
tance for better understanding of arterial stiffness 
mechanisms. In the control group of normotensive 
patients, the same analysis showed that the PWV 
value depended significantly on age only.
MMP-3 (stromelysin-1) plays an important 
regulatory role in the metabolism of connective 
tissue proteins. This enzyme initiates many pro-
cesses by exposing the collagen and elastin fibers 
from a  protective coating of proteoglycans and 
also activates the metalloproteinases responsible 
for their further degradation.
After 12 months of treatment with candesar-
tan in patients with arterial hypertension, Sasa-
mura et al. [39] observed a significant decrease in 
the value of the arterial stiffness index ankle-bra-
chial pulse wave velocity (abPWV), and an accom-
panying increase in the serum concentration of 
MMP-3. Moreover, the authors found a  statisti-
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Figure 1. Changes from baseline to final visit in 
carotid-femoral pulse wave velocity (in patients 
randomized to therapeutic subgroups (ANCOVA  
analysis)). Adjusted for age, gender, baseline PWV, 
systolic blood pressure, and reduction in SBP 
changes from baseline in mean PWV at visit 2 ( ),  
3 ( ) and 4 ( ). Error bars show SEM. P = 0.5179 
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cally significant relationship between a decrease 
of abPWV (ΔabPWV) and an increase of MMP-3 
(ΔMMP-3).
In the same study, Sasamura et al. found that 
the baseline abPWV and the baseline MMP-3 
values were not related; their result opposes our 
study observations. The different indices used for 
the evaluation of arterial stiffness may, to some 
extent, explain the observed differences.
The carotid-femoral PWV in our study may re-
flect changes in the aorta and large elastic arter-
ies. The ankle-brachial PWV in the study by Sa-
samura et al. also depended on the pulse wave 
propagation in smaller arteries with a  major 
contribution of the smooth muscle component. 
Another possible reason for the disparity is the 
different treatment period (6 months in our study 
and 12 months in the study by Sasamura et al.). 
This may explain why the obtained results in 
regard to MMP-3 changes (an increase in Sasamu-
ra’s study and a decrease in our study) during the 
treatment are conflicting.
The extent of the decrease in MMP-3 (ΔMMP-3) 
and PWV (ΔPWV) in our study was the same for 
all drug used, however these changes were not 
significantly associated, as it was demonstrated 
in Sasamura’s study.
The extent of carotid-femoral PWV reduction 
observed in our study was not dependent on the 
antihypertensive drug used, but rather depended 
on the extent of the reduction of the systolic blood 
pressure. These results are contrary to the results 
of Karalliedde et al. [10], who obtained a signifi-
cantly greater decrease in carotid-femoral PWV 
in patients treated with a valsartan/hydrochloro-
thiazide combination for 6 months, compared to 
treatment with amlodipine, with the same blood 
pressure lowering effect.
The independence of PWV lowering effect 
from the drug used, which makes a  difference 
between our study and Karalliede study can be 
explained by a  number of reasons: the use of 
valsartan/hydrochlorothiazide combination in 
one of the groups compared by Karalliedde et 
al. and monotherapy in all treatment subgroups 
in our study; the individual, selective, and more 
beneficial effect of valsartan than losartan on 
arterial stiffness; ethnic differences (i.e. com-
pared groups were ethnically diverse – only 47% 
of subjects were of white origin in the study by 
Karalliedde et al. and they were 100% white 
Caucasian in our study), different clinical char-
acteristics (only patients with isolated systolic 
hypertension and type 2 diabetes with microal-
buminuria were enrolled in the Karalliedde et al. 
study, while our study predominantly featured 
patients with mixed systolic-diastolic hyperten-
sion without diabetes (93.5%)). 
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Differences in the clinical characteristics of the 
study groups also resulted in significantly higher 
PWV values (average of 12 m/s) in Karalliedde’s 
group and lower values in our group of patients.
Therefore, this was potentially more difficult to 
reverse (not in the case of all drugs) in Karallied-
de’s group and easier in our group.
A  meta-analysis conducted by Ong et al. [11] 
suggested that ACEI are more effective in reduc-
ing arterial stiffness, compared to other drugs in 
long-term treatment; however, our results do not 
support such a conclusion. For us, the meta-anal-
ysis by Ong is not overall conclusive in this issue, 
although it is cited by the latest ESH/ESC guide-
lines [3]. 
The number of patients in this meta-analy-
sis in the long-term treatment arm (n = 185) is 
less than twice the number of patients in our 
prospective study (n = 95). Of the nine studies 
in this meta-analysis, most recruited well below 
19 patients in the active treatment group (one 
study had 28, and one had 17 patients). Each 
treatment subgroup of our study consisted of 
19 patients. In most studies of the meta-analysis 
discussed, in the “long-term” treatment arm, the 
treatment period was only 1 month (although in 
one study it was 3 months and in another it was 
6 months). Our results, which showed a  lack of 
difference in the reduction of PWV for 5 studied 
drugs, are based on a 6-month treatment period. 
Therefore we believe our results are of great prac-
tical therapeutic relevance, until large-scale clin-
ical trials provide more reliable evidence for the 
treatment guidelines in patients with systemic 
hypertension and arterial stiffness.
In the discussion of the results by Karalliedde 
et al. [10], they suggest that the superior effect 
in reducing arterial stiffness of the valsartan/hy-
drochlorothiazide combination compared to am-
lodipine is due to a specific effect on the activity 
of connective tissue matrix metalloproteinases. 
For all metalloproteinases investigated by us, 
a significant treatment effect observed was a re-
duction of serum concentration of MMP-2 and 
MMP-3 and an increase in the concentration of 
TIMP-1. All the compared agents decreased the 
concentration of MMP-2 and MMP-3, and in-
creased the concentration of TIMP-1 to the same 
extent, and the observed reduction of PWV was 
not dependent on changes in MMP-2, MMP-3 and 
TIMP-1 but was only dependent on a  change in 
systolic blood pressure. 
As in the study of Tan et al. [40] and Tayebjee 
et al. (Anglo-Scandinavian Cardiac Outcomes Trial 
ASCOT study) [31], and in contrast to the study of 
Li-Saw-Hee et al. [32] and Zervoudaki et al. [41], 
hypertensive patients in our study had higher lev-
els of MMP-9 gelatinase than the control group. 
Furthermore, in patients with hypertension we 
observed higher serum concentrations of anoth-
er gelatinase, MMP-2 and a decrease in its con-
centration due to antihypertensive treatment. 
Zervoudaki et al. [41] observed a  lower plasma 
concentration of MMP-2 in patients with arterial 
hypertension than in normotensives and an in-
crease in levels of both gelatinases, MMP-2 and 
MMP-9, as a result of antihypertensive treatment. 
The aforementioned gelatinases have proteolytic 
activity against isolated collagen fibers and gela-
tin. Their elevated levels in the serum accompany 
inflammation and the destabilization of athero-
sclerotic plaque. The level of MMP-9 in the ASCOT 
study correlated with higher risk of coronary heart 
disease [31], and in patients with coronary artery 
disease it was proven to be a predictor of cardio-
vascular mortality [42]. Elevated levels of MMP-2 
and MMP-9 in the serum of patients with hyper-
tension and decreasing concentrations of these 
gelatinases in the course of treatment appears 
to be the most likely situation, as observed in our 
study. 
A  meta-analysis published in 2012 dedicated 
to the significance of metalloproteinases in heart 
and vascular remodeling in patients with arterial 
hypertension confirms that levels of MMP-9 are 
elevated in hypertensive patients without heart 
failure, compared to normotonics. Additionally, 
elevated levels of MMP-2 were observed in hy-
pertensive patients and left ventricular diastolic 
failure, compared to patients with hypertension 
without diastolic failure [30]. The meta-analysis 
cited above also indicates the presence of elevat-
ed levels of TIMP-1 in patients with arterial hyper-
tension compared to normotonics and suggests 
in the final conclusion that MMP-2, MMP-9 and 
TIMP-1 may play a  role as biomarkers of cardio-
vascular remodeling in hypertension. 
The significance of TIMP-1 in the metabolism 
of structural proteins of the vascular wall is prob-
ably greater than that of any separately consid-
ered metalloproteinase, with the exception of 
MMP-3. The broad spectrum of TIMP-1 activities 
includes blocking activity of MMP-1, inhibition 
of other metalloproteinases, and involvement 
in the processes of angiogenesis, apoptosis and 
steroidogenesis [18]. TIMP-1 is sometimes consid-
ered a marker of fibrosis and, therefore, could be 
involved in the development of arterial stiffness. 
Lindsay et al. [43] described its role in the develop-
ment of fibrosis and myocardial stiffness. TIMP-1 
lowers the turnover of type I  collagen and prob-
ably increases the deposition of it in the arterial 
wall [43, 44], which could cause an increase in ar-
terial stiffness. 
Our results, however, do not support this hy-
pothesis. In patients with hypertension, the plas-
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ma levels of TIMP-1 were not higher than those 
in the control group, as in the study by Stakos 
et al. [45]. Plasma concentrations of TIMP-1 
showed no significant correlation with the PWV 
value as it was observed by Tayebjee et al. in the 
ASCOT study [31], where there was an increase of 
TIMP-1 rather than a decrease in the course of an-
tihypertensive treatment. The results of Tayebjee 
et al. [31], both in terms of sample size and ob-
servation time during treatment (3 years), seem 
to be the most reliable. Limitations of our study 
include a small sample size, although it was sim-
ilar to the majority of studies in which connective 
tissue matrix metalloproteinases were assessed. 
The second limitation of our study is the time of 
observation. We assumed 6 months of treatment 
as optimal for changes in PWV based on our pre-
vious experience. It is longer than in most of the 
studies that have assessed the effect of treatment 
on the change of PWV. Given the large heteroge-
neity of groups and discrepancies in the results of 
other studies that have evaluated the activity of 
metalloproteinases in patients with arterial hyper-
tension, it is difficult to clearly determine whether 
the period of 6 months is optimal for the assess-
ment of changes caused by treatment.
In conclusion, in patients with arterial hyper-
tension, beside age and systolic blood pressure, 
the determinants of arterial stiffness include se-
rum MMP-3 concentration. For drugs compared 
in the study with the same hypotensive effect ob-
tained, the arterial stiffness reduction effect is not 
dependent on the drug used. Systolic blood pres-
sure is one of the independent factors responsible 
for the reduction of arterial stiffness in the course 
of antihypertensive treatment.
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